San Antonio Breast Cancer Symposium

Dr Banu Arun on Technologies to Expand Access to Genetic Counseling

December 15, 2019

There are new technologies that allow for genetic counseling services through which the provider does not even need to get that involved in the process, said Banu Arun, MD, medical oncologist, Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center.

Dr Erica Mayer on Improving Patient Adherence to Hormonal Therapies

December 14, 2019

Listening to patient concerns and issues and communicating with them can really help providers keep patients with breast cancer adherent to their hormonal therapies, said Erica Mayer, MD, MPH, assistant professor, medicine, Harvard Medical School.

Personalizing Breast Cancer: How Liquid Biopsy Testing for ctDNA, CTCs Can Promote Preventive Care

December 14, 2019

Two abstracts on liquid biopsy tests revealed the potential of analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in promoting heightened decision-making by clinicians for patients with early-stage and metastatic breast cancer.

Oral Paclitaxel Reveals Superior Confirmed Response, Survival in Patients With Metastatic Breast Cancer, Compared With IV Paclitaxel

December 14, 2019

In phase 3 trial results presented at the San Antonio Breast Cancer Symposium in San Antonio, Texas, oral paclitaxel with encequidar, the first orally administered paclitaxel, was shown to exhibit superior confirmed response and survival with less neuropathy for patients with metastatic breast cancer compared with intravenous (IV) paclitaxel.

Dr Corey Speers on Challenges Adopting Personalized Radiation Therapy

December 13, 2019

Ensuring that prognostic or predictive tests to help make decisions regarding radiation therapy are accurate and clinically validated remains a challenge, said Corey Speers, MD, PhD, assistant professor, radiation oncology, University of Michigan.

Age Associated With Benefit Derived From Chemotherapy for Women With Luminal Breast Cancer, MINDACT Trial Finds

December 13, 2019

Data from the MINDACT trial revealed that among women with luminal breast cancers (hormone receptor–positive, HER2-negative by local pathology) with a high clinical risk and low genomic risk, those aged 40 to 50 years had a greater, but insignificant, benefit from chemotherapy than patients older than 50.

Dr Nadine Tung Discusses When to Refer Patients for Germline Testing

December 13, 2019

The bar for who should get genetic testing for breast cancer keeps getting lowered, and oncologists have to keep informed about which results should trigger a referral for germline testing, said Nadine Tung, MD, director, Cancer Risk and Prevention Program, Beth Israel Deaconess Medical Center, and associate professor, medicine, Harvard Medical School.

Dr Eileen Rakovitch Outlines Use of Biomarkers to Treat Breast Cancer

December 13, 2019

Using biomarker tests can help personalize care for women with ductal carcinoma in situ and determine the risks of using or not using radiation, said Eileen Rakovitch, MD, MSc, FRCPC, professor, department of radiation oncology, University of Toronto.

Measuring Therapeutic Intervention Impact, Receptiveness for Patients With Breast Cancer

December 12, 2019

In 3 abstracts presented at the San Antonio Breast Cancer Symposium in San Antonio, Texas, patient-reported outcomes (PROs) and quality of life were measured for different therapeutic interventions aiming to either heighten tumor detection or ease chemotherapy-induced effects.